Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + oxaliplatin + 5-fluorouracil/leucovorin in second-line advanced or metastatic pancreatic cancer
ChiCTR2400094119Phase 4Not yet recruiting
- Sponsor
- Wuxi People's Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome, oxaliplatin, fluorouracil and folinic acid in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Wuxi People's Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
irinotecan liposomeoxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400094119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094119.